By the time a blockbuster drug’s first Paragraph IV challenger is ready to launch, the brand manufacturer has often already […]

Argentina’s pharmaceutical market is a $7.3 billion commercial arena projected to reach $14.2 billion by 2030 — and it is

The three most consequential generic drug launches in pharmaceutical history share almost nothing in surface mechanics. One ended in a

The global generic drug industry saves the U.S. healthcare system roughly $2.9 trillion per decade. In high-income markets, this model

Biologic drugs generate more revenue per product than any other class of medicine. They also carry more patents, attract more

The Hatch-Waxman Act created the modern generic drug industry in 1984. Forty years later, the Paragraph IV certification it established

The Patent Trial and Appeal Board has quietly become the most consequential forum in pharmaceutical IP. This is the definitive

Every year, pharmaceutical companies collectively forfeit billions in potential patent term by misusing one of the most misunderstood tools in

Two off-patent molecules. A single tablet. A decade of exclusivity and margins that rival any branded biologic. That is the